Investment Trusts

International Biotechnology Trust

IBT:LSE

International Biotechnology Trust

Actions
  • Price (GBX)681.00
  • Today's Change3.00 / 0.44%
  • Shares traded5.82k
  • 1 Year change+3.18%
  • Beta0.1885
Data delayed at least 20 minutes, as of Sep 13 2024 08:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Total returns on £1000

1Y
Fund/benchmarkChange
PriceInternational Biotechnology Trust (Ordinary Share)+6.74%
NAVInternational Biotechnology Trust (Ordinary Share)+13.67%
Morningstar's BenchmarkNasdaq Biotechnology Index--

Key statistics

As of last trade International Biotechnology Trust (IBT:LSE) traded at 681.00, -5.42% below its 52-week high of 720.00, set on Jul 26, 2024.
52-week range
Today
548.00Oct 27 2023720.00Jul 26 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding36.77m
Market cap247.86m GBP
Total assets300.73m GBP
Total expense ratio1.44%
High686.00
Low678.00
Previous close678.00
Average volume69.96k
YTD Change+6.07%
Beta0.1885
Diluted NAV (est)747.97
Diluted NAV (last pub)751.50
Premium/Discount-10.14%
Net Gearing+5.61%
Annual div (ADY)28.40
GBX
Annual div yield (ADY)4.21%
Div ex-dateJul 25 2024
Div pay-dateAug 23 2024
Data delayed at least 20 minutes, as of Sep 13 2024 08:40 BST.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.